314 related articles for article (PubMed ID: 36291874)
1. GOF Mutant p53 in Cancers: A Therapeutic Challenge.
Dolma L; Muller PAJ
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291874
[No Abstract] [Full Text] [Related]
2. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
3. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
5. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
Nishikawa S; Iwakuma T
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672377
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53.
Datta A; Dey S; Das P; Alam SK; Roychoudhury S
Genom Data; 2016 Jun; 8():47-51. PubMed ID: 27114909
[TBL] [Abstract][Full Text] [Related]
9. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
10. Targeting mutant p53 in cancer: the latest insights.
Di Agostino S; Fontemaggi G; Strano S; Blandino G; D'Orazi G
J Exp Clin Cancer Res; 2019 Jul; 38(1):290. PubMed ID: 31277687
[TBL] [Abstract][Full Text] [Related]
11. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
13. The Development of p53-Targeted Therapies for Human Cancers.
Lu Y; Wu M; Xu Y; Yu L
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509223
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
15. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
16. Targeting Oncogenic Mutant p53 for Cancer Therapy.
Parrales A; Iwakuma T
Front Oncol; 2015; 5():288. PubMed ID: 26732534
[TBL] [Abstract][Full Text] [Related]
17. Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment.
Bhatta B; Luz I; Krueger C; Teo FX; Lane DP; Sabapathy K; Cooks T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203762
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
[TBL] [Abstract][Full Text] [Related]
20. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
